Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "annual"

1082 News Found

Lupin launches Ganirelix Acetate Injection in US
News | February 16, 2024

Lupin launches Ganirelix Acetate Injection in US

It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation


Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
News | February 14, 2024

Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US

Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.


Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar
Healthcare | February 13, 2024

Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar

Launches collaborative centre for translational research in head and neck cancer


Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg
Drug Approval | February 10, 2024

Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions


Wellify adopts Unicommerce to streamline E-commerce operations
Supply Chain | February 07, 2024

Wellify adopts Unicommerce to streamline E-commerce operations

The company will be managing orders and warehouse operations for Little's, Lacto-calamine, Tri-activ, I-feel, Ourdaily, and Sloan's through the Unicommerce platform


Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew
News | January 30, 2024

Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew

Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material


EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer
Drug Approval | January 29, 2024

EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival


Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Drug Approval | January 26, 2024

Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia